Skip to main content

Animations

MJFF Publications

3221 - 3230 of 9034 Results
Title
Year
  • Year
  • 2020
  • 2020
  • 2023
  • 2023
  • 2023
  • 2019
  • 2020
  • 2021
  • 2021
  • 2015
  • Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial
    2020
    Summary Details
    RESTRICTED
    Title: Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30136-8
    Citation Count: 143
  • Summary Details
    OPEN
    Title: Developing therapies for Parkinson's disease
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30320-3
    Citation Count: 7
  • α-synuclein seed amplification in Parkinson‘s disease
    2023
    Summary Details
    RESTRICTED
    Title: α-synuclein seed amplification in Parkinson‘s disease
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: RESTRICTED
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(23)00373-3
    Citation Count: 3
  • α-synuclein seed amplification in Parkinson's disease – Authors' reply
    2023
    Summary Details
    OPEN
    Title: α-synuclein seed amplification in Parkinson's disease – Authors' reply
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(23)00371-x
    Citation Count: 7
  • Summary Details
    OPEN
    Title: α-synuclein seed amplification in Parkinson‘s disease
    Journal Name: The Lancet Neurology
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s1474-4422(23)00374-5
    Citation Count: 3
  • Summary Details
    OPEN
    Title: Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study
    Journal Name: The Lancet Digital Health
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/s2589-7500(19)30105-0
    Citation Count: 116
  • Summary Details
    OPEN
    Title: Assessment of LIN28A variants in Parkinson's disease in large European cohorts
    Journal Name: Neurobiology of Aging
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2020.12.002
    Citation Count: 6
  • Summary Details
    OPEN
    Title: Analysis of PTRHD1 common and rare variants in European patients with Parkinson's disease
    Journal Name: Neurobiology of Aging
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: other-oa
    DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2021.06.005
    Citation Count: 6
  • Summary Details
    OPEN
    Title: LRRK2 p.M1646T is associated with glucocerebrosidase activity and with Parkinson's disease
    Journal Name: Neurobiology of Aging
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neurobiolaging.2021.02.018
    Citation Count: 25
  • Summary Details
    OPEN
    Title: Parkinson's disease biomarkers program brain imaging repository
    Journal Name: NeuroImage
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License:
    DOI - Digital Object Identifier: 10.1016/j.neuroimage.2015.05.005
    Citation Count: 26
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.